

28 February 2014

### **Mr David Williams to join the Calzada Board**

Calzada Ltd ("Calzada") is pleased to announce the appointment of Mr David Williams as a Non-executive Director with immediate effect.

Mr Williams is an experienced Director and Investment Banker with a proven track record in business development and strategy, mergers and acquisitions and capital raising. He has 30 years' experience working with and advising ASX listed companies in the food, medical device and pharmaceutical sectors.

Mr Williams is currently Chairman of Medical Developments International Ltd. (ASX:MVP), Director of IDT Ltd. (ASX:IDT) and Managing Director of corporate advisory firm Kidder Williams Ltd. Prior to this he was the Managing Director of Challenger Corporate Finance, Head of Mergers & Acquisitions at Société Générale, Head of Mergers & Acquisitions at ANZ McCaughan, and Head of Mergers & Acquisitions at Arthur Andersen & Co. He has been Chairman of Tassal Group Ltd. and held numerous other Directorships including with Amcal Ltd. and Select Harvests Ltd.

Commenting on his appointment, Mr Williams said "I am excited about joining the Calzada Board and for the opportunity to apply my skills and experience to assist in directing the commercialization of Calzada's unique polymer medical device technology and pharmaceutical product."

The Chairman of Calzada, Dr Roger Aston said that "Calzada is very pleased to attract someone of the caliber of David to the Board. His strong corporate skills and professional networks as well as his vast experience in building and maximizing the value of companies will be of great value to Calzada."

#### **For further information please contact:**

Dr Roger Aston  
Chairman  
Calzada Limited  
Mobile: 0402 762 204  
Email: rogeraston@aol.com

David Williams  
Mobile: 0414 383 593



Calzada Limited  
ABN 96 083 866 862

2/320 Lorimer Street, Port Melbourne VIC 3207  
Tel: +61 3 8681 4050 Fax: +61 3 8681 4099

#### **About Calzada Ltd**

Calzada has 100% ownership of PolyNovo Biomaterials Pty Ltd and Metabolic Pharmaceuticals Pty Ltd. The Company is listed on the Australian Securities Exchange (ASX Code CZD).

#### **About PolyNovo Biomaterials Pty Ltd**

PolyNovo owns and develops a suite of state of the art biodegradable polymers that have potential applications across numerous medical fields.

#### **About Metabolic Pharmaceuticals Pty Ltd**

Metabolic's asset is the AOD9604 peptide which has potential applications in the treatment of obesity, bone, cartilage and muscle diseases and repair.